Twelve Points Wealth Management LLC Buys 20,843 Shares of The Chemours Company $CC

Key Points

• Twelve Points Wealth Management LLC increased its stake in The Chemours Company by 17.1%, acquiring an additional 20,843 shares during the second quarter, bringing its total ownership to 142,875 shares valued at approximately $1.636 million.
• Chemours has seen a range of analyst ratings, with Royal Bank of Canada and Mizuho both boosting their price targets, resulting in a consensus "Moderate Buy" rating and an average price target of $17.63.
• The company recently declared a quarterly dividend of $0.0875 per share, resulting in an annualized yield of 2.2%, despite a current negative net margin of -7.19%.

Twelve Points Wealth Management LLC grew its stake in shares of The Chemours Company (NYSE:CC - Free Report) by 17.1% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 142,875 shares of the specialty chemicals company's stock after buying an additional 20,843 shares during the quarter. Twelve Points Wealth Management LLC owned 0.10% of Chemours worth $1,636,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. State of Alaska Department of Revenue grew its stake in shares of Chemours by 7.6% during the second quarter. State of Alaska Department of Revenue now owns 89,091 shares of the specialty chemicals company's stock valued at $1,019,000 after buying an additional 6,305 shares during the last quarter. Counterpoint Mutual Funds LLC purchased a new stake in Chemours in the 2nd quarter worth $316,000. GAMMA Investing LLC lifted its stake in Chemours by 130.7% in the 2nd quarter. GAMMA Investing LLC now owns 3,175 shares of the specialty chemicals company's stock worth $36,000 after purchasing an additional 1,799 shares in the last quarter. U.S. Capital Wealth Advisors LLC purchased a new stake in Chemours in the 2nd quarter worth $117,000. Finally, Matrix Trust Co lifted its stake in Chemours by 69.2% in the 2nd quarter. Matrix Trust Co now owns 27,765 shares of the specialty chemicals company's stock worth $318,000 after purchasing an additional 11,357 shares in the last quarter. 76.26% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. Royal Bank Of Canada boosted their price target on shares of Chemours from $14.00 to $15.00 and gave the stock an "outperform" rating in a research note on Thursday, July 3rd. Truist Financial boosted their price target on shares of Chemours from $18.00 to $21.00 and gave the stock a "buy" rating in a research note on Tuesday, September 16th. Zacks Research upgraded shares of Chemours from a "strong sell" rating to a "hold" rating in a report on Wednesday, August 27th. Finally, Mizuho boosted their target price on shares of Chemours from $16.00 to $19.00 and gave the stock an "outperform" rating in a report on Tuesday. Five investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, Chemours currently has a consensus rating of "Moderate Buy" and a consensus price target of $17.63.

Chemours Stock Performance

Chemours stock opened at $15.66 on Friday. The company's 50-day moving average price is $14.79 and its 200-day moving average price is $12.94. The Chemours Company has a twelve month low of $9.13 and a twelve month high of $22.38. The company has a quick ratio of 0.83, a current ratio of 1.68 and a debt-to-equity ratio of 17.16. The company has a market cap of $2.34 billion, a PE ratio of -5.59 and a beta of 1.61.

Chemours (NYSE:CC - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The specialty chemicals company reported $0.58 EPS for the quarter, beating the consensus estimate of $0.46 by $0.12. The company had revenue of $1.62 billion for the quarter, compared to the consensus estimate of $1.57 billion. Chemours had a negative net margin of 7.19% and a positive return on equity of 35.14%. The firm's revenue was up 5.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.38 EPS. Chemours has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, equities research analysts forecast that The Chemours Company will post 2.03 EPS for the current fiscal year.

Chemours Cuts Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, September 12th. Investors of record on Friday, August 15th were issued a dividend of $0.0875 per share. This represents a $0.35 annualized dividend and a yield of 2.2%. The ex-dividend date was Friday, August 15th. Chemours's dividend payout ratio is presently -12.50%.

Insider Buying and Selling

In other news, CEO Denise Dignam purchased 4,068 shares of the business's stock in a transaction that occurred on Friday, August 8th. The shares were bought at an average cost of $12.06 per share, for a total transaction of $49,060.08. Following the acquisition, the chief executive officer owned 191,546 shares of the company's stock, valued at approximately $2,310,044.76. This trade represents a 2.17% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 0.47% of the company's stock.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.

Want to see what other hedge funds are holding CC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Chemours Company (NYSE:CC - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.